Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Tomoko Sugihara"'
Autor:
Lisa M. Hess, Patrick Peterson, Tomoko Sugihara, Naleen Raj Bhandari, Peter M. Krein, Anthony Sireci
Publikováno v:
Cancer Treatment and Research Communications, Vol 37, Iss , Pp 100761- (2023)
Objectives: This study compared outcomes between patients with biomarker-positive advanced/metastatic non-small cell lung cancer (a/mNSCLC) who initiated treatment with targeted therapy versus those who initiated chemotherapy-based treatment and swit
Externí odkaz:
https://doaj.org/article/22a0aa08d379490ebe10a39f872dce36
Publikováno v:
Cancer Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Abstract Background Administration of doxorubicin by continuous intravenous (CIV) infusion, versus bolus (BOL) administration, has been proposed to mitigate the risk of cardiac events. This study used real‐world data to explore the association betw
Externí odkaz:
https://doaj.org/article/c819c8ccaf324cd994fe3885dd48b845
Autor:
Ikuko Tanaka, Masayo Sato, Tomoko Sugihara, Douglas E. Faries, Shuko Nojiri, Peita Graham-Clarke, Jennifer A. Flynn, Russel T. Burge
Publikováno v:
Journal of Osteoporosis, Vol 2013 (2013)
Adherence and persistence with osteoporosis treatments are essential for reducing fracture risk. Once-daily teriparatide is available in Japan for treating osteoporosis in patients with a high risk of fracture. The study objective was to describe rea
Externí odkaz:
https://doaj.org/article/e1d3b5cbf195444dab8b0f2ffb4c9682
Autor:
Toby A. Eyre, Lisa M. Hess, Tomoko Sugihara, Dan He, Manoj Khanal, John M. Pagel, Richard A. Walgren, Paolo B. Abada, Heiko Konig, Lindsey E. Roeker, Anthony Mato
Publikováno v:
Leukemia & Lymphoma. :1-12
Autor:
Josephine Feliciano, Katherine B. Winfree, Zhanglin Lin Cui, Kristin M Sheffield, Tomoko Sugihara
Publikováno v:
Current Medical Research and Opinion. 38:91-99
This retrospective, observational study examined patient characteristics, treatment patterns, testing patterns, and outcomes of US patients receiving first-/second- or third-generation epidermal gr...
Publikováno v:
Cancer reports (Hoboken, N.J.)REFERENCES.
Administration of doxorubicin by continuous intravenous (CIV) infusion, versus bolus (BOL) administration, has been proposed to mitigate the risk of cardiac events. This study used real-world data to explore the association between mode of doxorubici
Autor:
Kristin M Sheffield, Jessica R Peachey, Michael Method, Brenda R Grimes, Jacqueline Brown, Kim Saverno, Tomoko Sugihara, Zhanglin Lin Cui, Kimberley T Lee
Publikováno v:
Future oncology (London, England). 18(21)
Aim: To assess invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, HER2-negative early breast cancer with combined clinicopathological criteria from monarchE, a phase III study of abemaciclib.
Autor:
Tomoko Sugihara, Lisa M. Hess, Hannah M. Linden, Lee D. Cranmer, Poorni Manohar, Yajun E Zhu, Howard G Muntz
Publikováno v:
Cancer Research. 81:PS13-38
Background While novel targeted agents are increasingly used to care for patients with breast cancer, doxorubicin (DOX) continues to play a role in management of patients, particularly those with aggressive disease. Dose-dependent cardiomyopathy is a
Autor:
Katherine B, Winfree, Kristin M, Sheffield, Zhanglin Lin, Cui, Tomoko, Sugihara, Josephine, Feliciano
Publikováno v:
Current medical research and opinion. 38(1)
This retrospective, observational study examined patient characteristics, treatment patterns, testing patterns, and outcomes of US patients receiving first-/second- or third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Publikováno v:
Journal of Clinical Oncology. 38:e19123-e19123
e19123 Background: Doxorubicin continues to play a central role in management of breast cancer and sarcomas. Dose-dependent cardiomyopathy is a challenge in its use. Strategies have been proposed to mitigate this, including administration by continuo